US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.11 against a street estimate of 0.11 — a beat of 0.0%.
Analysts rate Warby Parker Inc a buy (9 buy, 6 hold, 0 sell out of 15) with an average price target of $30.15.
| Fund | Stake |
|---|---|
| FMR Inc | 12.65% |
| JPMorgan Chase & Co | 8.22% |
| BlackRock Inc | 5.92% |
| Durable Capital Partners LP | 5.21% |
| Vanguard Portfolio Management, LLC | 4.34% |
| Vanguard Capital Management, LLC | 3.59% |
| Vaughan Nelson Scarbrgh & Mccullough LP | 2.53% |
| State Street Corp | 1.98% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-12 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-26 |
| Results announced · Q1 2026 | 2026-02-26 |
| Board / officer change · Q1 2026 | 2026-02-09 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Warby Parker Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.